Estrogen replacement and migraine

Maturitas

Volumn 63, Issue 1, 2009, Pages 51-55

  MacGregor, E A ^a,b  

^a City of London Migraine Clinic   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aura; Estrogen; Hormone therapy; Menopause; Migraine

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE; SEX HORMONE;

BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; HEADACHE; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; MENSTRUAL MIGRAINE; MENSTRUATION; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTIPLE CYCLE TREATMENT; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; STROKE;

BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MIGRAINE DISORDERS; MIGRAINE WITH AURA; PERIMENOPAUSE; POSTMENOPAUSE; RISK FACTORS; STROKE;

EID: 67349263046     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.03.016     Document Type: Review

References (70)

1. World Health Organization. Mental health: new understanding, New Hope. Geneva: WHO; 2001.
2. Stovner L., Hagen K., Jensen R., et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27 March(3) (2007) 193-210
3. Stewart W.F., Wood C., Reed M.L., Roy J., and Lipton R.B. Cumulative lifetime migraine incidence in women and men. Cephalalgia 28 11 (2008) 1170-1178
4. Rasmussen B.K., and Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 12 August(4) (1992) 221-228 discussion 186
5. Headache Classification Subcommittee of the International Headache Society (IHS). The international classification of headache disorders (2nd ed.) Cephalalgia 2004; 24(Suppl. 1):1-160.
6. Russell M.B., and Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 119 April(Pt 2) (1996) 355-361
7. Couturier E.G., Bomhof M.A., Neven A.K., and van Duijn N.P. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 23 May(4) (2003) 302-308
8. Granella F., Sances G., Zanferrari C., Costa A., Martignoni E., and Manzoni G.C. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 33 July-August(7) (1993) 385-389
9. MacGregor E.A., Chia H., Vohrah R.C., and Wilkinson M. Migraine and menstruation: a pilot study. Cephalalgia 10 December(6) (1990) 305-310
10. MacGregor E.A., Brandes J., Eikermann A., and Giammarco R. Impact of migraine on patients and their families: the migraine and zolmitriptan evaluation (MAZE) survey-Phase III. Curr Med Res Opin 20 July(7) (2004) 1143-1150
11. Somerville B.W. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 22 4 (1972) 355-365
12. Somerville B.W. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology 25 3 (1975) 239-244
13. Somerville B.W. Estrogen-withdrawal migraine. II. Attempted prophylaxis by continuous estradiol administration. Neurology 25 3 (1975) 245-250
14. Somerville B.W. The role of progesterone in menstrual migraine. Neurology 21 8 (1971) 853-859
15. Epstein M.T., Hockaday J.M., and Hockaday T.D. Migraine and reproductive hormones throughout the menstrual cycle. Lancet 1 March(7906) (1975) 543-548
16. Lichten E.M., Lichten J.B., Whitty A., and Pieper D. The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test. Headache 36 June(6) (1996) 367-371
17. Pfaffenrath V. Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine. Cephalalgia 13 Suppl. 13 (1993) 244
18. Pradalier A., Vincent D., Beaulieu P., Baudesson G., and Launey J.-M. Correlation between estradiol plasma level and therapeutic effect on menstrual migraine. In: Rose F. (Ed). New advances in headache research (1994), Smith-Gordon, London 129-132
19. Smits M.G., van der Meer Y.G., Pfeil J.P., Rijnierse J.J., and Vos A.J. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache 34 February(2) (1994) 103-106
20. de Lignieres B., Vincens M., Mauvais-Jarvis P., Mas J.L., Touboul P.J., and Bousser M.G. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed) 293 December(6561) (1986) 1540
21. Dennerstein L., Morse C., Burrows G., Oats J., Brown J., and Smith M. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 2 (1988) 113-120
22. MacGregor E.A., Frith A., Ellis J., Aspinall L., and Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology September(67) (2006) 2154-2158
23. MacGregor E.A., Frith A., Ellis J., Aspinall L., and Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 67 (2006) 2159-2163
24. Martin V., Wernke S., Mandell K., et al. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache 43 April(4) (2003) 309-321
25. Freeman E.W., Sammel M.D., Lin H., Gracia C.R., and Kapoor S. Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 111 January(1) (2008) 127-136
26. Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache 43 January(1) (2003) 27-35
27. Wang S.J., Fuh J.L., Lu S.R., Juang K.D., and Wang P.H. Migraine prevalence during menopausal transition. Headache 43 May(5) (2003) 470-478
28. Neri I., Granella F., Nappi R., Manzoni G.C., Facchinetti F., and Genazzani A.R. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 17 July(1) (1993) 31-37
29. Oldenhave A., Jaszmann L.J., Everaerd W.T., and Haspels A.A. Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age. Am J Obstet Gynecol 168 3 Pt 1 (1993) 765-771
30. Sabia S., Fournier A., Mesrine S., Boutron-Ruault M.C., and Clavel-Chapelon F. Risk factors for onset of menopausal symptoms results from a large cohort study. Maturitas 60 June(2) (2008) 108-121
31. Mueller L. Predictability of exogenous hormone effect on subgroups of migraineurs. Headache 40 March(3) (2000) 189-193
32. Aegidius K.L., Zwart J.A., Hagen K., Schei B., and Stovner L.J. Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol 14 January(1) (2007) 73-78
33. Misakian A.L., Langer R.D., Bensenor I.M., et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt) 12 December(10) (2003) 1027-1036
34. Hodson J., Thompson J., and al-Azzawi F. Headache at menopause and in hormone replacement therapy users. Climacteric 3 June(2) (2000) 119-124
35. Moorhead T., Hannaford P., and Warskyj M. Prevalence and characteristics associated with use of hormone replacement therapy in Britain. Br J Obstet Gynaecol 104 March(3) (1997) 290-297
36. Warren M.P., and Kulak Jr. J. Is estrogen replacement indicated in perimenopausal women?. Clin Obstet Gynecol 41 December(4) (1998) 976-987
37. MacGregor A. Effects of oral and transdermal estrogen replacement on migraine. Cephalalgia 19 (1999) 124-125
38. Kudrow L. The relationship of headache frequency to hormone use in migraine. Headache 15 1 (1975) 36-40
39. Nappi R.E., Cagnacci A., Granella F., Piccinini F., Polatti F., and Facchinetti F. Course of primary headaches during hormone replacement therapy. Maturitas 38 April(2) (2001) 157-163
40. Kurth T., Gaziano J.M., Cook N.R., Logroscino G., Diener H.-C., and Buring J.E. Migraine and risk of cardiovascular disease in women. JAMA 296 3 (2006) 283-291
41. Kaiser H.J., and Meienberg O. Deterioration of onset of migraine under oestrogen replacement therapy in the menopause. J Neurol Neurosurg Psychiat 240 3 (1993) 195-197
42. MacGregor A. Estrogen replacement and migraine aura. Headache 39 (1999) 674-678
43. Nagel-Leiby S., Welch K.M., Grunfeld S., and D'Andrea G. Ovarian steroid levels in migraine with and without aura. Cephalalgia 10 3 (1990) 147-152
44. Stang P.E., Carson A.P., Rose K.M., et al. Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology 64 May(9) (2005) 1573-1577
45. MacClellan L.R., Giles W., Cole J., et al. Probable migraine with visual aura and risk of ischemic stroke. The stroke prevention in young women study. Stroke 38 (2007) 2438-2445
46. Kurth T., Schurks M., Logroscino G., Gaziano J.M., and Buring J.E. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 337 aug07_1 (2008) a636
47. Henrich J.B., and Horwitz L.A. A controlled study of ischemic stroke risk in migraine patients. J Clin Epidemiol 42 (1989) 773-780
48. Tzourio C., Iglesias S., Hubert J.B., et al. Migraine and risk of ischaemic stroke: a case-control study. BMJ 307 July(6899) (1993) 289-292
49. Tzourio C., Tehindrazanarivelo A., Iglesias S., et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 310 April(6983) (1995) 830-833
50. Carolei A., Marini C., and De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet 347 June(9014) (1996) 1503-1506
51. Chang C, Donaghy M, Poulter N, et al. Migraine and stroke in young women: case-control study. BMJ 1999; 318:13-8.
52. Nightingale A.L., and Farmer R.D. Ischemic stroke in young women: a nested case-control study using the UK General Practice Research Database. Stroke 35 July(7) (2004) 1574-1578
53. Kurth T., Slomke M.A., Kase C.S., et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 64 6 (2005) 1020-1026
54. Scher A.I., Terwindt G.M., Picavet H.S., Verschuren W.M., Ferrari M.D., and Launer L.J. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 64 February(4) (2005) 614-620
55. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005;330(7482):63-5.
56. Luyer M.D., Khosla S., Owen W.G., and Miller V.M. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 86 August(8) (2001) 3629-3634
57. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002 Jun 20;89(12A):12E-7E; [discussion 7E-8E].
58. Kruit M.C., van Buchem M.A., Hofman P.A.M., et al. Migraine as a risk factor for subclinical brain lesions. JAMA 291 4 (2004) 427-434
59. Scher A.I., Terwindt G.M., Verschuren W.M., et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol 59 February(2) (2006) 372-375
60. Rubino E., Ferrero M., Rainero I., Binello E., Vaula G., and Pinessi L. Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis. Cephalalgia August (2007)
61. Schurks M., Zee R.Y., Buring J.E., and Kurth T. Interrelationships among the MTHFR 677C>T polymorphism, migraine, and cardiovascular disease. Neurology 71 August(7) (2008) 505-513
62. Schwaiger J., Kiechl S., Stockner H., et al. Burden of atherosclerosis and risk of venous thromboembolism in patients with migraine. Neurology 71 September(12) (2008) 937-943
63. Crassard I., Conard J., and Bousser M.G. Migraine and haemostasis. Cephalalgia 21 July(6) (2001) 630-636
64. Moschiano F., D'Amico D., Ciusani E., et al. Coagulation abnormalities in migraine and ischaemic cerebrovascular disease: a link between migraine and ischaemic stroke?. Neurol Sci 25 Suppl. 3 (2004) S126-S128
65. Zegura B., Guzic-Salobir B., Sebestjen M., and Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 13 July-August(4) (2006) 643-650
66. Brosnan J.F., Sheppard B.L., and Norris L.A. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?. Thromb Haemost 97 April(4) (2007) 558-565
67. Fait T., Vrablik M., Zizka Z., and Kostirova M. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study. Gynecol Obstet Invest 65 1 (2008) 47-51
68. Eilertsen A.L., Qvigstad E., Andersen T.O., Sandvik L., and Sandset P.M. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 55 October(3) (2006) 278-287
69. Pines A., Sturdee D.W., Birkhauser M.H., Schneider H.P., Gambacciani M., and Panay N. IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 10 June(3) (2007) 181-194
70. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11(January-February(1)):11-33.